2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Terminated
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Plasma cell
1
Other hematologic neoplasm
1
Other
1
Myeloid
1
Conditions
Mucositis
4
Hematologic Neoplasms
3
Lymphoma, Non-Hodgkin
2
Hodgkin Disease
2
Unspecified Adult Solid Tumor, Protocol Specific
1
Thrombocytopenia
1
Sarcoma
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neutropenia
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Lymphopenia
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Graft vs Host Disease
1
Cytopenia
1
Chondrosarcoma
1
Bone Neoplasms
1
Anemia
1
Interventions
Rituximab
344
Cyclophosphamide
317
fludarabine phosphate
142
Etoposide
139
Peripheral Blood Stem Cell Transplantation
124
fludarabine
112
Filgrastim
112
Mycophenolic Acid
98
Melphalan
98
Whole-Body Irradiation
90
Vincristine
90
Busulfan
87
Cytarabine
85
Doxorubicin
79
Cyclosporine
76
Tacrolimus
75
Radiotherapy
75
Prednisone
73
Bendamustine Hydrochloride
72
Granulocyte Colony-Stimulating Factor
66
Methotrexate
65
Antilymphocyte Serum
56
Carmustine
54
Dexamethasone
50
Gemcitabine
48
Lenalidomide
46
Bortezomib
43
venetoclax
41
ibritumomab tiuxetan
37
obinutuzumab
36
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Lymphoma, Non-Hodgkin
×
angiotensin I (1-7)
×
Clear all
NCT01121120
2020-12-08
TXA127-PBSC
Tarix Pharmaceuticals
Phase 2
Terminated
75 enrolled
NCT01300611
2020-12-08
USBTXA127CBT
Tarix Pharmaceuticals
Phase 1
Terminated
20 enrolled